Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 3:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 1,033 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Clotting Disorder Clear all
Not listed No phase listed Observational

Study of Genetic and Molecular Defects in Primary Immunodeficiency Disorders

NCT00004341
View directory record Official record
Conditions
X-Linked Agammaglobulinemia, X-Linked Hyper IgM Syndrome, Wiskott-Aldrich Syndrome, Leukocyte Adhesion Deficiency Syndrome
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
0 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1995
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 20, 2026, 3:21 AM EDT
Terminated Phase 2 Interventional Results available

Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)

NCT03123588
View directory record Official record
Conditions
MPN (Myeloproliferative Neoplasms)
Interventions
Ruxolitinib, Anagrelide, Placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
26
States / cities
Phoenix, Arizona • Long Beach, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2021 · Synced Oct 20, 2026, 3:21 AM EDT
Completed Early Phase 1 Interventional

Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases

NCT00424242
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Metastatic Cancer, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Secondary Myelofibrosis, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
Pemetrexed
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 120 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 8, 2021 · Synced Oct 20, 2026, 3:21 AM EDT
Completed No phase listed Observational

Evaluation of the Reasons and Consequences of Bleeding in Late Teens and Early Adulthood Patients With Severe Hemophilia A

NCT00782470
View directory record Official record
Conditions
Hematologic Disease, Blood Coagulation Disorders
Interventions
Recombinant Factor VIII (Kogenate, BAY 14-2222)
Behavioral
Lead sponsor
Bayer
Industry
Eligibility
14 Years to 29 Years · Male only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
7
States / cities
Duarte, California • Denver, Colorado • Peoria, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2014 · Synced Oct 20, 2026, 3:21 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Phase 1/2 Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Glanzmann Thrombasthenia

NCT06211634
View directory record Official record
Conditions
Glanzmann Thrombasthenia
Interventions
HMB-001
Drug
Lead sponsor
Hemab ApS
Industry
Eligibility
18 Years to 67 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
5
States / cities
La Jolla, California • New Orleans, Louisiana • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 20, 2026, 3:21 AM EDT
Recruiting Not applicable Interventional

Anti-Reflux Endoscopic TX Using APC (AREA) in GERD Patients: (The AREA Study)

NCT05570448
View directory record Official record
Conditions
Gastro Esophageal Reflux
Interventions
ARAT, Sham intervention (control)
Procedure
Lead sponsor
Midwest Veterans' Biomedical Research Foundation
Other
Eligibility
18 Years to 80 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 20, 2026, 3:21 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Participants From Birth to 12 Months of Age With Hemophilia A Without Inhibitors

NCT04431726
View directory record Official record
Conditions
Severe Hemophilia A
Interventions
Emicizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
0 Months to 12 Months
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
6
States / cities
Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 20, 2026, 3:21 AM EDT
Terminated Phase 2 Interventional Results available

Azacitidine in Treating Patients With Myelofibrosis

NCT00381693
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Secondary Myelofibrosis
Interventions
azacitidine
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 21, 2011 · Synced Oct 20, 2026, 3:21 AM EDT
Terminated No phase listed Observational

The Epidemiology of Bleeding and Clotting in Patients Undergoing Heart Transplantation, Coronary Artery Bypass Graft Surgery,or Implantation of Left Ventricular Assist Devices

NCT01481012
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
13
States / cities
Birmingham, Alabama • San Diego, California • Oak Lawn, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2011 · Synced Oct 20, 2026, 3:21 AM EDT
Not listed Phase 1 Interventional

Combination Chemotherapy Plus Amifostine in Treating Patients With Advanced Cancer

NCT00004036
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Drug/Agent Toxicity by Tissue/Organ, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
sargramostim, amifostine trihydrate, carboplatin, cyclophosphamide
Biological · Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 19, 2013 · Synced Oct 20, 2026, 3:21 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Reference Range Analysis of the Entegrion Point of Care Coagulation Monitor (PCM™) in Healthy Volunteers

NCT03133351
View directory record Official record
Conditions
Coagulation
Interventions
PCM
Device
Lead sponsor
Entegrion, Inc.
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
2
States / cities
St Louis, Missouri • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 16, 2020 · Synced Oct 20, 2026, 3:21 AM EDT
Completed No phase listed Observational

Retrospective Study to Capture Dosing and Treatment Outcome Data in Participants With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND

NCT00161720
View directory record Official record
Conditions
Protein C Deficiency
Interventions
Protein C Concentrate (Human) Vapor Heated
Drug
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
Not listed
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
10
States / cities
Los Angeles, California • Denver, Colorado • Fort Carson, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Oct 20, 2026, 3:21 AM EDT
Completed Phase 2 Interventional Results available

Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies

NCT02556931
View directory record Official record
Conditions
Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Chronic Myeloid Leukemia, Chronic Myeloproliferative Disorders, Multiple Myeloma, Plasma Cell Neoplasm, Plasma Cell Dyscrasia, Myelofibrosis, Polycythemia Vera, Essential Thrombocythemia, Plasma Cell Leukemia
Interventions
Fludarabine, Cyclophosphamide, Total body irradiation, Tacrolimus, Mycophenolate mofetil
Drug · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
Not listed
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 3, 2022 · Synced Oct 20, 2026, 3:21 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Gene Transfer Study for Hemophilia A

NCT03003533
View directory record Official record
Conditions
Hemophilia A
Interventions
SPK-8011
Genetic
Lead sponsor
Spark Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
11
States / cities
Sacramento, California • Gainesville, Florida • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2024 · Synced Oct 20, 2026, 3:21 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Motor Proficiency of People With Bleeding Disorders Using the BOT-2 (TM)

NCT02279199
View directory record Official record
Conditions
Hemophilia
Interventions
Not listed
Lead sponsor
Oregon Health and Science University
Other
Eligibility
4 Years to 21 Years · Male only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2022
U.S. locations
2
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 11, 2023 · Synced Oct 20, 2026, 3:21 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Factor IX Gene Therapy Study (FIX-GT)

NCT03369444
View directory record Official record
Conditions
Hemophilia B
Interventions
FLT180a
Biological
Lead sponsor
University College, London
Other
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 2, 2022 · Synced Oct 20, 2026, 3:21 AM EDT
Completed Phase 2 Interventional

Phase II Study of Rituximab in Patients With Immune Thrombocytopenic Purpura

NCT00005652
View directory record Official record
Conditions
Purpura, Thrombocytopenic, Idiopathic
Interventions
rituximab
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 9, 2008 · Synced Oct 20, 2026, 3:21 AM EDT
Withdrawn Phase 4 Interventional

Pilot Study to Compare Fresh Frozen Plasma With 24-Hour Plasma in Babies Up to Age Six Months

NCT02774317
View directory record Official record
Conditions
Blood Coagulation Disorders
Interventions
Plasma
Biological
Lead sponsor
University of Chicago
Other
Eligibility
Up to 6 Months
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 24, 2018 · Synced Oct 20, 2026, 3:21 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of Coagulation in Multiple Sclerosis

NCT01711255
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Bastyr University
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Kenmore, Washington
Source: ClinicalTrials.gov public record
Updated Jul 28, 2017 · Synced Oct 20, 2026, 3:21 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of Recombinant Factor XIII for Prevention of Bleeding in Patients With FXIII Inherited Deficiency

NCT00713648
View directory record Official record
Conditions
Congenital Bleeding Disorder, Congenital FXIII Deficiency
Interventions
catridecacog
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
6 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
11
States / cities
Phoenix, Arizona • Orange, California • Tampa, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2017 · Synced Oct 20, 2026, 3:21 AM EDT
Completed Phase 2 Interventional Results available

The Effect of Rivaroxaban in Sickle Cell Disease

NCT02072668
View directory record Official record
Conditions
Sickle Cell Anemia, Sickle Cell-Beta0-Thalassemia
Interventions
rivaroxaban, placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 13, 2020 · Synced Oct 20, 2026, 3:21 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders

NCT00157079
View directory record Official record
Conditions
Primary Immunodeficiency Diseases (PID), Immune Thrombocytopenic Purpura (ITP), Kawasaki Syndrome
Interventions
Immune Globulin Intravenous (Human), 10%
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
24 Months and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
11
States / cities
Los Angeles, California • Stanford, California • Englewood, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2021 · Synced Oct 20, 2026, 3:21 AM EDT
Completed Phase 2Phase 3 Interventional

Efficacy and Safety Study of Protein C Concentrate in Subjects With Severe Congenital Protein C Deficiency

NCT00157118
View directory record Official record
Conditions
Protein C Deficiency
Interventions
Protein C Concentrate (Human) Vapor Heated
Drug
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
Not listed
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
12
States / cities
Los Angeles, California • Denver, Colorado • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated May 5, 2021 · Synced Oct 20, 2026, 3:21 AM EDT
Active, not recruiting No phase listed Observational

An Observational Study of Participants With Type 3 Von Willebrand Disease on Prophylactic Standard-of-Care Treatment

NCT06883240
View directory record Official record
Conditions
Von Willebrand Disease, Type 3
Interventions
Von Willebrand Factor Concentrates, Von Willebrand Factor Concentrates and Factor VIII Concentrates, Factor VIII Concentrates, Recombinant Activated Factor VII, Activated Prothrombin Complex Concentrate
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
2 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
Sacramento, California • Minneapolis, Minnesota • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 20, 2026, 3:21 AM EDT